The earnings call presented a mixed picture with notable revenue growth and strategic acquisitions offset by a decline in adjusted EBITDA, financial asset losses, and increased operating expenses. While there are promising developments in the promoted portfolio and upcoming product launches, financial challenges need to be addressed.

Company Guidance -

Q2 2025

During Knight Therapeutics' first-quarter 2025 conference call, the company reported revenues of $88 million, marking a 3% year-over-year increase, primarily driven by a 16% growth in their promoted portfolio. Adjusted EBITDA stood at over $12 million, with a decrease of 11% from the previous year. The oncology and hematology portfolio contributed $32 million, growing by 3%, while the infectious disease portfolio reported $36 million, a 4% decline. Knight also highlighted significant transactions, including the $100 million acquisition of Paladin's assets and the expansion with Helsinn to include Onicit in specific Latin American markets. Financial guidance for fiscal 2025 anticipates revenues between $390 million and $405 million, with an adjusted EBITDA margin of approximately 13%. The company also executed a share buyback under the NCIB and secured a $40 million line of credit to support their financial strategy.

Revenue Growth

Knight Therapeutics reported revenues of $88 million for Q1 2025, an increase of $2 million or 3% over the same period last year.

Promoted Portfolio Performance

The promoted portfolio, accounting for over 75% of total revenues, grew by $9 million or 16% on a constant currency basis.

Oncology and Hematology Portfolio Growth

This portfolio delivered $32 million in revenues, a growth of $1 million or 3%, and $2 million or 6% on a constant currency basis.

Infectious Disease Portfolio Growth on Constant Currency

Despite a nominal decrease, the portfolio grew by $1 million or 3% on a constant currency basis.

Pipeline and Product Launches

Knight continued to advance its portfolio with regulatory submissions and approvals, launching Minjuvi in Mexico and relaunching Onicit in Brazil and Mexico.

Paladin Acquisition

Knight entered into an agreement to acquire the assets of Paladin for $100 million plus $20 million of inventory, with potential future contingent payments up to $15 million.

Financial Outlook for 2025

Knight expects to generate revenues between $390 million to $405 million and an adjusted EBITDA of approximately 13% of revenues.

Knight Therapeutics (KHTRF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KHTRF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2025	2025 (Q2)	0.01 / -	-0.014	―	―	―
May 08, 2025	2025 (Q1)	<0.01 / 0.01	-0.029	150.00% (+0.04)	―
Mar 20, 2025	2024 (Q4)	0.01 / 0.08	-0.166	147.83% (+0.25)	―
Nov 07, 2024	2024 (Q3)	0.01 / 0.00	0.065	―	―
Aug 08, 2024	2024 (Q2)	0.02 / -0.01	0.014	-200.00% (-0.03)	―
May 09, 2024	2024 (Q1)	<0.01 / -0.03	-0.029	0.00% (0.00)	―
Mar 21, 2024	2023 (Q4)	>-0.01 / -0.17	-0.094	-76.92% (-0.07)	―
Nov 09, 2023	2023 (Q3)	-0.02 / 0.06	0.007	800.00% (+0.06)	―
Aug 10, 2023	2023 (Q2)	>-0.01 / 0.01	0.014	0.00% (0.00)	―
May 11, 2023	2023 (Q1)	-0.03 / -0.03	-0.115	75.00% (+0.09)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

KHTRF Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 08, 2025	$4.38	$4.08	-6.85%
Mar 20, 2025	$4.36	$4.39	+0.69%
Nov 07, 2024	$4.11	$3.73	-9.25%
Aug 08, 2024	$4.01	$4.19	+4.49%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Knight Therapeutics (KHTRF) report earnings?

Knight Therapeutics (KHTRF) is schdueled to report earning on Aug 07, 2025, Before Open (Confirmed).

What is Knight Therapeutics (KHTRF) earnings time?

Knight Therapeutics (KHTRF) earnings time is at Aug 07, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is KHTRF EPS forecast?

KHTRF EPS forecast for the fiscal quarter 2025 (Q2) is 0.01.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing